Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Roskamp Institute Stories

2013-11-12 08:37:18

GLEN ALLEN, Va., Nov. 12, 2013 /PRNewswire/ -- Star Scientific, Inc., (NASDAQ: STSI) today filed with the Securities and Exchange Commission its Form 10-Q for the quarter ended September 30, 2013. The Company reported net sales totaling $2.3 million for the three months ending September 30, 2013, compared with net sales of $1.7 million for the same period in 2012. Net sales for the nine months ending September 30, 2013, totaled $7.3 million, compared with $4.2 million for the same...

2013-11-07 12:29:15

GLEN ALLEN, Va., Nov. 7, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announced that the Company has filed its preliminary proxy statement on Form 14A with the Securities and Exchange Commission in preparation for its December 27 annual shareholder meeting. The proxy statement outlines the Company's plan to accelerate the submission of an Investigational New Drug (IND) application to the FDA, with the assistance of a respected global contract research organization (CRO)....

2013-01-31 12:28:04

GLEN ALLEN, Va., Jan. 31, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces publication of the first peer-reviewed article examining the effects of anatabine in a mouse model of the debilitating autoimmune and neurodegenerative disease multiple sclerosis (MS). The study, conducted by the Company's research partner, The Roskamp Institute, was designed to determine whether anatabine had beneficial effects on the development of experimental autoimmune encephalomyelitis...

2013-01-28 12:25:55

GLEN ALLEN, Va., Jan. 28, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) commented today on a January 23, 2013, column appearing on TheStreet.com. That piece contains numerous false and misleading statements regarding the Company's anatabine research and the initial results of the ASAP Human Thyroid Health Study released by Star Scientific on January 7, 2013. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) As reported in the Company's January 7, 2013, press...

2012-11-27 12:27:15

GLEN ALLEN, Va., Nov. 27, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces that new anatabine research has been accepted by and published online in the European Journal of Pharmacology. In a series of studies, researchers at the Roskamp Institute demonstrated that anatabine can suppress brain inflammation in animal models of Alzheimer's disease, inflammation in the blood in mice, and inflammation induced in human blood once removed from the body. This peer-reviewed...

2012-10-17 11:23:53

GLEN ALLEN, Va., Oct. 17, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented research this week showing that anatabine supplementation reduces the pathology and signs in an animal model of Alzheimer's disease. The findings were presented in New Orleans, Louisiana, at Neuroscience 2012, the 42nd annual meeting of the Society for...

2012-10-16 11:25:42

GLEN ALLEN, Va., Oct. 16, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that earlier in the week scientists from its research partner, the Roskamp Institute, presented results of its recent research showing that anatabine supplementation significantly reduces central and peripheral inflammation and neurological injury in an animal model of multiple sclerosis (MS). The findings were presented in New...

2012-10-15 11:28:25

GLEN ALLEN, Va., Oct. 15, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented new research yesterday and today indicating that supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement, has the potential to alleviate the negative consequences of traumatic brain injury (TBI). These...

2012-08-23 06:25:34

GLEN ALLEN, Va., Aug. 23, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary Rock Creek Pharmaceuticals Inc., announced today that the Alzheimer's study of the company's dietary supplement Anatabloc(® )has screened and enrolled its first patient. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) The Alzheimer's study, entitled, "A Three Month, Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to...

2012-05-08 06:31:06

GLEN ALLEN, Va., May 8, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., announces that it has received important new research findings from its research partner, The Roskamp Institute of Sarasota, Florida. The Institute has completed a successful animal study of nutritional supplementation with Rock Creek's specially formulated anatabine (patent pending), in an animal model of multiple sclerosis. The Roskamp...